康方生物今日盘中股价大幅上涨5.24%，引起了市场的广泛关注。
消息面上，康方生物近期在研发管线方面取得多项积极进展。公司在AACR年会上公布了全球首创PD-1/CTLA-4双特异性抗体卡度尼利（AK104）联合化疗一线治疗晚期胰腺癌的II期临床研究（COMPASSION-26）的优异数据，结果显示该联合方案在局部晚期不可手术患者中展现出良好的抗肿瘤活性和生存获益。此外，公司全球首创的三特异性抗体新药AK150已获得临床试验默示许可。
同时，康方生物的另一款核心产品依沃西（PD-1/VEGF双抗）联合疗法用于治疗晚期胆道癌，已被纳入突破性治疗药物名单，其III期临床研究已完成患者入组。这些积极的研发里程碑增强了市场对公司创新能力和长期增长潜力的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.